Goodwin Advises Prime Medicine in Collaboration With Bristol Myers Squibb to Develop Multiple Ex Vivo T-Cell Therapies, With $110M Upfront, Up to $3.5B in Milestones
October 02, 2024
October 02, 2024
BOSTON, Massachusetts, Oct. 2 -- Goodwin, a law firm, issued the following news release:
Goodwin's Life Sciences team advised Prime Medicine on a strategic research collaboration and license agreement with Bristol Myers Squibb to develop reagents for the next generation of ex vivo T-cell therapies. Prime Medicine's PASSIGE technology combines Prime Editing, a versatile, precise and efficient gene editing technology, with an integrase or other site-specific recombinase to i . . .
Goodwin's Life Sciences team advised Prime Medicine on a strategic research collaboration and license agreement with Bristol Myers Squibb to develop reagents for the next generation of ex vivo T-cell therapies. Prime Medicine's PASSIGE technology combines Prime Editing, a versatile, precise and efficient gene editing technology, with an integrase or other site-specific recombinase to i . . .